DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Kwality Pharmaceuticals Limited (KPL) share price today?

Kwality Pharmaceuticals Limited (KPL) is trading at ₹3,370 on the NSE, up 1.63% on the day. Source: DocStoX.

What is the PE ratio of Kwality Pharmaceuticals Limited?

Kwality Pharmaceuticals Limited has a price-to-earnings (PE) ratio of 51.9 in the Healthcare sector.

What is the market capitalisation of Kwality Pharmaceuticals Limited?

Kwality Pharmaceuticals Limited has a market capitalisation of approximately ₹3,525 crore.

Is Kwality Pharmaceuticals Limited a profitable company?

Kwality Pharmaceuticals Limited generates a return on equity of 22.6% with a net profit margin of 13.3%. That is a strong return on shareholder capital.

What is the 52-week high and low of KPL?

Kwality Pharmaceuticals Limited (KPL) has traded between ₹1,561 and ₹3,949 over the past 52 weeks, against a current price of ₹3,370.

Kwality Pharmaceuticals Limited

₹3,370.00▲ +54.10 (+1.63%)

KPL·NSE·Healthcare

Market Cap

3524.54 Cr

PE Ratio

51.92

Volume

18,366

Day High - Low

3448.80 - 3325.00

52W High-Low

3949.00 - 1561.00

₹3,370.00▲ +54.10 (+1.63%)

Market Cap3524.54 Cr

PE Ratio51.92

Volume18,366

Day High - Low3448.80 - 3325.00

52W High-Low3949.00 - 1561.00

Kwality Pharmaceuticals Limited (KPL): company summary

The company's business is improving, with annual revenue rising 35.9% and annual net profit jumping 67.5%.

Kwality Pharmaceuticals Limited (KPL) is a micro-cap Healthcare company valued at ₹3,525 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Kwality Pharmaceuticals Limited last traded at ₹3,370, modestly up 1.63% on the day.
Recent developments: 2026-06-30: The company reported its latest quarter results, showing significant growth in both revenue and net profit compared to the same quarter a year earlier. 2026-06-30: Promoter holding remained at 54.86%, while foreign institutional holding increased by 0.34 percentage points and domestic institutional holding rose by 0.20 percentage points.
Financial performance: The company's business is improving, with annual revenue rising 35.9% and annual net profit jumping 67.5%. The latest quarter saw revenue surge 45.9% and net profit leap 116.7% compared to the same quarter a year earlier. Net profit margin widened 2.5 percentage points to 13.3%, while return on equity and return on capital employed remained strong at 22.6% and 24.0%, respectively.
Valuation multiples: The stock trades at 51.9 times earnings, a premium to the Healthcare median of 32.0, 8.58 times book value.
Things to watch: The company has not paid out any dividends despite reporting repeated profits. The stock is 9.7% below its 52-week high, and the market cap is ₹3,709 crore, classifying it as a micro-cap. The company's debt to equity ratio is 0.39, indicating moderate leverage.
Where it stands: Kwality Pharmaceuticals L has shown strong growth in both revenue and net profit, with the latest quarter reflecting a significant increase compared to the same period a year ago. The company's net profit margin has widened, and its return on equity and return on capital employed remain robust. The stock is currently 9.7% below its 52-week high.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.3/10

Fair

Fair Value

ROE

22.60%

Strong

P/E

51.92x

Expensive

Debt / Equity

0.39

Moderate

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹3325

₹3449

52W₹1561

₹3949

DocStoX take

Supported by growth (8.7) and quality (7.7), but held back by valuation (0.0). Growth looks strong at 8.7, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.3

/10

Fair

Quality

Excellent

ROE 22.6%

Valuation

Expensive

P/E 51.9×

Growth

Strong

Revenue +13.9% 5Y CAGR

Risk

Moderate

D/E 0.39

Momentum

Strong

76% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹3,370

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹3,525 Cr

52W High / Low

₹3949 / ₹1561

Dividend Yield

0.00%

Promoter Holding

54.86%

EPS (TTM)

₹64.91

Book Value

₹320.00

Key highlights

Profit compounding 35% a year
Profitable in all of the last 5 years
Capital works hard — ROCE 24%
Valuation is weak (0.0/10)

4 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Kwality Pharmaceuticals Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Kwality Pharmaceuticals Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Kwality Pharmaceuticals Limited with peers

Kwality Pharmaceuticals Limited vs Sun Pharmaceutical Industries Limited Kwality Pharmaceuticals Limited vs Divi's Laboratories Limited Kwality Pharmaceuticals Limited vs Torrent Pharmaceuticals Limited Kwality Pharmaceuticals Limited vs Apollo Hospitals Enterprise Limited Kwality Pharmaceuticals Limited vs Zydus Lifesciences Limited Kwality Pharmaceuticals Limited vs Laurus Labs Limited

Related tools & concepts

Value Kwality Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

KPL newsLatest coverage & filings Open screenerFilter the whole market